METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo drug study for advanced prostate cancer
Disease control OngoingThis study looked at how two drugs, JNJ-56021927 and abiraterone acetate, interact in men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to check safety and find the right doses. Fifty-seven men took part, and the results help doctors under…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 02:13 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in men with prostate cancer that has spread and is no longer responding to standard treatments. The drug delivers a radioactive payload directly to cancer cells that have a specific marker (PSMA). The study…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 02:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study tests a new treatment called Lu-177-PNT2002 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment delivers radiation directly to cancer cells using a targeting molecule. About 455 men will participate to see if it slo…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing nearby he…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis early-phase study tested a combination of two drugs—nivolumab (an immunotherapy) and Radium-223 (a radioactive drug)—in 39 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goals were to check safety and see if…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise in slowing advanced prostate cancer
Disease control OngoingThis study tests whether adding olaparib to standard treatment (abiraterone) can help men with a certain type of advanced prostate cancer live longer without their cancer getting worse. About 895 men who have not had chemotherapy or newer hormone drugs for this stage of cancer ar…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial underway
Disease control OngoingThis study tests a drug called enfortumab vedotin, alone or with other medicines, in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to shrink tumors or slow the disease. About 34 men who have already tried chemotherapy will take part.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for tough prostate cancer: targeted radiation trial launches
Disease control OngoingThis study tests a new drug, FPI-2265, which delivers targeted radiation to prostate cancer cells. It is for adults with a specific type of advanced prostate cancer (PSMA-positive mCRPC) that has worsened after prior treatment with another radiation therapy. The goal is to find t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug duo shows promise in slowing tough prostate cancer
Disease control OngoingThis study tests whether adding olaparib to standard abiraterone therapy can delay cancer growth in men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet had chemotherapy or newer hormone drugs. About 110 participants will receive either the combinatio…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for veterans with tough prostate cancer: targeted drug shows promise
Disease control OngoingThis study tests a drug called pembrolizumab in 40 veterans whose prostate cancer has spread and stopped responding to hormone therapy. The cancer must have certain gene changes (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors o…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo therapy shows promise for tough prostate cancer
Disease control OngoingThis study tests a new drug combination (FPI-2265 and olaparib) in 85 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the treatment can shrink tumors and lower PSA levels while monitoring side effects. Participants must have tri…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New alpha therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis phase II trial tests a new drug called FPI-2265 for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful radioactive particle directly to cancer cells. The main goal is to see if it can lower PSA levels by a…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug combo shows promise in Hard-to-Treat prostate cancer
Disease control OngoingThis study tested whether a targeted chemotherapy drug (abemaciclib) alone or combined with an immunotherapy drug (atezolizumab) can shrink or slow advanced prostate cancer that no longer responds to hormone therapy. 19 men with metastatic castration-resistant prostate cancer too…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Promising prostate cancer trial pulled before it even started
Disease control TerminatedThis study was withdrawn before enrolling any participants. It planned to test a radioactive drug called 177Lu-PSMA-617 in men with advanced prostate cancer that had spread to the bone marrow and caused low blood cell counts. The goal was to see if the drug was safe and could hel…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New radiation therapy aims to control Hard-to-Treat prostate cancer
Disease control ENROLLING_BY_INVITATIONThis study tests a new treatment called 177Lu-HTK03170 for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The treatment delivers radiation directly to cancer cells using a targeting molecule. The goal is to find a safe dose and see if …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Experimental cell therapy targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not to cure the disease. Participants must have meta…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new treatment for men with advanced prostate cancer that has stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Up to 18 participants …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Targeted drug shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study compares the drug olaparib to standard treatments (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone therapy and who have BRCA1/2 gene mutations. The goal is to see if olaparib can delay cancer growth bette…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
New hope for tough prostate cancer: RS-113 drug trial underway
Disease control OngoingThis study tests a new drug called RS-113 in 120 men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the best dose that can slow or stop cancer growth, comparing it to an existing drug, abiraterone. Participant…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Double attack on tough prostate cancer: chemo meets targeted radiation
Disease control OngoingThis study tests whether adding a chemotherapy drug called carboplatin to a targeted radiation treatment (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that no longer responds to hormone therapy. About 37 participants will receive the combination to …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
New combo therapy aims to slow advanced prostate cancer
Disease control OngoingThis study tests a new drug combination (ONC-392 plus lutetium) in people with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. About 148 participants will be randomly assigned to receive the combination or an active control. The goal is…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
New imaging agent could reveal hidden prostate cancer
Diagnosis OngoingThis early-phase study tests a new PET imaging agent (89Zr-DFO-YS5) designed to find a protein called CD46 on prostate cancer cells in men with advanced, treatment-resistant prostate cancer. About 30 participants will receive the agent and undergo PET scans to see if it can accur…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated May 17, 2026 02:08 UTC
-
New registry to track PSMA therapy results in advanced prostate cancer
Knowledge-focused OngoingThis study is a registry that collects information on 500 men with metastatic castration-resistant prostate cancer who are treated with PSMA theranostics. The main goal is to see how many men have a significant drop in PSA levels after treatment. Researchers will also track side …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC